{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T20:52:41Z","timestamp":1782679961033,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cancer Council SA\u2019s Beat Cancer Project on behalf of its donors and the State Government of South Australia through the Department of Health","award":["XXXXXX"],"award-info":[{"award-number":["XXXXXX"]}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation, Australia","doi-asserted-by":"crossref","award":["PF-17-007"],"award-info":[{"award-number":["PF-17-007"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Rash is one of the most common severe adverse events associated with use of vemurafenib for the treatment of melanoma, either as monotherapy or in combination with cobimetinib. The study aimed to identify pre-treatment patient characteristics predictive of developing severe rash with vemurafenib therapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This was a secondary pooled analysis of individual patient data from the BRIM-2, BRIM-3 and coBRIM clinical trials, including all patients treated with vemurafenib alone and vemurafenib plus cobimetinib. Patient age, sex, performance status, body weight, body mass index, liver function markers and estimated glomerular filtration rate were assessed for association with development of severe (grade 3 or 4) rash using logistic regression.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of 962 patients treated with vemurafenib, 150 (16%) patients experienced severe rash. Female sex was identified as a significant risk factor for severe rash development (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), having a two-fold increased risk compared to males (22% vs 11%, odds ratio [OR] 2.17; 95% CI 1.52 to 3.09). Low body weight was also associated with increased risk of severe rash (<jats:italic>P<\/jats:italic>\u2009=\u20090.002), but this association was not significant after adjustment for sex. The association between sex and risk of severe rash was consistent across clinical trials and treatments (vemurafenib monotherapy, vemurafenib plus cobimetinib).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Females had approximately two-fold increased risk of developing severe rash compared to males in clinical trials of vemurafenib alone or in combination with cobimetinib.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-6659-0","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T10:02:32Z","timestamp":1582797752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-4378","authenticated-orcid":false,"given":"Ashley M.","family":"Hopkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash D.","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganessan","family":"Kichenadasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Sorich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"issue":"26","key":"6659_CR1","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","journal-title":"N Engl J Med"},{"issue":"9839","key":"6659_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358\u201365.","journal-title":"Lancet"},{"issue":"9","key":"6659_CR3","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, McArthur GA, Dr\u00e9no B, Atkinson V, Liszkay G, Di Giacomo AM, Mandal\u00e0 M, Demidov L, Stroyakovskiy D, Thomas L, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248\u201360.","journal-title":"Lancet Oncol"},{"issue":"20","key":"6659_CR4","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877\u201388.","journal-title":"N Engl J Med"},{"issue":"5","key":"6659_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603\u201315.","journal-title":"Lancet Oncol"},{"key":"6659_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/5361569","volume":"2016","author":"Bilgen Gen\u00e7ler","year":"2016","unstructured":"Gen\u00e7ler B, G\u00f6n\u00fcl M. Cutaneous side effects of BRAF inhibitors in advanced melanoma: review of the literature. Dermatol Res Pract. 2016;2016:\u20135361569.","journal-title":"Dermatology Research and Practice"},{"issue":"3","key":"6659_CR7","doi-asserted-by":"publisher","first-page":"e58721","DOI":"10.1371\/journal.pone.0058721","volume":"8","author":"JD Rinderknecht","year":"2013","unstructured":"Rinderknecht JD, Goldinger SM, Rozati S, Kamarashev J, Kerl K, French LE, Dummer R, Belloni B. RASopathic skin eruptions during Vemurafenib therapy. PLoS One. 2013;8(3):e58721.","journal-title":"PLoS One"},{"issue":"2","key":"6659_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.critrevonc.2013.06.002","volume":"88","author":"M Mandal\u00e0","year":"2013","unstructured":"Mandal\u00e0 M, Massi D, De Giorgi V. Cutaneous toxicities of BRAF inhibitors: clinical and pathological challenges and call to action. Crit Rev Oncol Hematol. 2013;88(2):318\u201337.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"6659_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323\u201332.","journal-title":"Lancet Oncol"},{"issue":"5","key":"6659_CR10","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/annonc\/mdx040","volume":"28","author":"B Dr\u00e9no","year":"2017","unstructured":"Dr\u00e9no B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, Grob JJ, Koralek DO, Rooney I, Hsu JJ, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 2017;28(5):1137\u201344.","journal-title":"Ann Oncol"},{"issue":"8","key":"6659_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa1112302","volume":"366","author":"JA Sosman","year":"2012","unstructured":"Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, et al. Survival in BRAF V600\u2013mutant advanced melanoma treated with Vemurafenib. N Engl J Med. 2012;366(8):707\u201314.","journal-title":"N Engl J Med"},{"key":"6659_CR12","unstructured":"https:\/\/clinicalstudydatarequest.com\/Study-Sponsors\/Study-Sponsors-Roche.aspx. Accessed 19 July 2019."},{"key":"6659_CR13","unstructured":"https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event. Accessed 19 June 2019."},{"issue":"3","key":"6659_CR14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","volume":"18","author":"ME Lacouture","year":"2013","unstructured":"Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, Kim CC, McCormack CJ, Myskowski PL, Spleiss O, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18(3):314\u201322.","journal-title":"Oncologist"},{"key":"6659_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature08833","volume":"464","author":"G Hatzivassiliou","year":"2010","unstructured":"Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJC, Stokoe D, Gloor SL, Vigers G, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464:431.","journal-title":"Nature"},{"issue":"5","key":"6659_CR16","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","volume":"167","author":"RM Anforth","year":"2012","unstructured":"Anforth RM, Blumetti TCMP, Kefford RF, Sharma R, Scolyer RA, Kossard S, Long GV, Fernandez-Pe\u00f1as P. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012;167(5):1153\u201360.","journal-title":"Br J Dermatol"},{"issue":"3","key":"6659_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1105358","volume":"366","author":"F Su","year":"2012","unstructured":"Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207\u201315.","journal-title":"N Engl J Med"},{"issue":"5","key":"6659_CR18","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/bjd.12010","volume":"167","author":"R Sinha","year":"2012","unstructured":"Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol. 2012;167(5):987\u201394.","journal-title":"Br J Dermatol"},{"issue":"1","key":"6659_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11523-015-0375-8","volume":"11","author":"N Kramkimel","year":"2016","unstructured":"Kramkimel N, Thomas-Schoemann A, Sakji L, Golmard J, Noe G, Regnier-Rosencher E, Chapuis N, Maubec E, Vidal M, Avril M, et al. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma. Target Oncol. 2016;11(1):59\u201369.","journal-title":"Target Oncol"},{"issue":"9","key":"6659_CR20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s40262-017-0523-7","volume":"56","author":"W Zhang","year":"2017","unstructured":"Zhang W, Heinzmann D, Grippo JF. Clinical pharmacokinetics of Vemurafenib. Clin Pharmacokinet. 2017;56(9):1033\u201343.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"6659_CR21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6659-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-6659-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6659-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:13:40Z","timestamp":1614298420000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-6659-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6659"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-6659-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"11 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Secondary analysis of participant-level data for the BRIM-2, BRIM-3 and coBRIM clinical studies was approved by the Southern Adelaide Clinical Human Research Ethics Committee (SAC HREC EC00188) and accessed according to Roche\u2019s policy and process for clinical study data sharing [].The trials conducted by Roche were performed in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki. Protocol approval was obtained from an independent ethics committee at each study site. All patients provided written informed consent [, , ].","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Sorich and Dr. Rowland report grants from Pfizer, outside the submitted work. No potential conflicts of interest were reported by the other authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}